primary antibodies against rabbit anti cd36  (Proteintech)

Journal: Chinese Medicine

Article Title: Combination of mangiferin and T0901317 targeting autophagy promotes cholesterol efflux from macrophage foam cell in atherosclerosis

doi: 10.1186/s13020-023-00876-9

Figure Lengend Snippet: Effects of mangiferin (MGF) and T0901317 (T0) on inhibition of AS progression. Apoe −/− mice fed with high fat diet (HFD) in four groups (n = 10/group) received the following treatment for 16 weeks. Ctrl: vehicle; T0: oral gavage of T0 (1 mg∙kg −1 bodyweight/day); MGF: oral gavage of MGF (200 mg kg −1 bodyweight/day); T0 + MGF: oral gavage of T0 and MGF. After treatment, aortas were collected for the following assays. A Lesions in en face aorta were determined by Oil Red O staining and lesion areas were expressed as % of total en face aorta areas. Scale bar, 5 mm. *** p < 0.001, ** p < 0.01, * p < 0.05, NS: not significant (n = 10). B Sinus lesions in aortic root were determined by Oil Red O staining and lesion areas were expressed as μm 2 /section. Scale bar, 400 μm. * p < 0.05 (n = 9). C Collagen content areas were determined by Masson staining of aortic root cross sections and quantified by a computer-assisted image analysis protocol (n = 3). Scale bar, 100 μm. D Expression of α-SMA (stained with red fluorescent color) was determined by immunofluorescent staining of aortic root cross sections and quantified by a computer-assisted image analysis protocol. Scale bar, 100 μm. *** p < 0.001, ** p < 0.01, * p < 0.05 (n = 3)

Article Snippet: Primary rabbit polyclonal antibodies against α-SMA (14395), CD36 (18836), Beclin1 (11306), ATG5 (10181), and ATG7 (10088) were purchased from Proteintech Group, Inc. (Rosemont, IL, USA).

Techniques: Inhibition, Staining, Expressing

Journal: Liver International

Article Title: Hypoxia‐inducible factor 2α drives hepatosteatosis through the fatty acid translocase CD36

doi: 10.1111/liv.14519

Figure Lengend Snippet: HIF2α silencing reduces both lipid accumulation and induction of CD36 expression in human liver cells submitted to hypoxic conditions. Huh7 cells infected with scrambled (shC) or HIF2α shRNA (shHIF2) lentiviral particles maintained under normoxic (Nx, 21% O2), or hypoxic conditions (Hp, 1% O2) in a hypoxia chamber for 36h. A, HIF2A mRNA levels in normoxia. B, Representative blots with the indicated antibodies and densitometric analysis from all blots. C, PHD3, EPO and PGK1 mRNA levels. D, (left panel) Representative experiment of Nile Red fluorescence intensity. (right panel) Analysis of intracellular lipid content by Nile Red staining. E, CD36 mRNA levels. * P < .05 and *** P < .005, Hp vs Nx; ## P < .01 and ### P < .005, shHIF2 vs shC (n = 4 independent experiments performed by duplicate)

Article Snippet: Paraffin‐embedded liver biopsy sections (4 μm thick) were immunostained with a primary rabbit antibody against HIF2α (ab199, Abcam) or CD36 (NB400‐144, Novus) diluted to 1:50 and 1:200 respectively, using the DAKO EnVisionTM+ System (DAKO, Glostrup, Denmark) as described by the manufacturer.

Techniques: Expressing, Infection, shRNA, Fluorescence, Staining

Journal: Liver International

Article Title: Hypoxia‐inducible factor 2α drives hepatosteatosis through the fatty acid translocase CD36

doi: 10.1111/liv.14519

Figure Lengend Snippet: Lack of HIF2α reverts Vhl inactivation‐induced NASH. A, Hepatic Vhl and Hif2a mRNA levels. B, Representative 10X images of haematoxylin/eosin (H&E) staining. Scale bar 100 µm. C, NAFLD activity score, steatosis grade, lobular inflammation and hepatocellular ballooning grade. D, Representative 20X images of Oil Red O (ORO) staining, and its quantification. Scale bar 100 µm. E, Hepatic Epo , Pgk1 and Cd36 mRNA levels. Experimental groups: Control, Vhl f/f ‐deficient mice and Vhl f/f Hif2α f/f ‐deficient mice (n = 6‐8 animals/group). * P < .05, ** P < .01 and *** P < .005, Vhl f/f or Vhl f/f Hif2α f/f ‐deficient vs Control mice; # P < .05, ## P < .01 and ### P < .005, Vhl f/f Hif2α f/f vs Vhl f/f ‐deficient mice

Article Snippet: Paraffin‐embedded liver biopsy sections (4 μm thick) were immunostained with a primary rabbit antibody against HIF2α (ab199, Abcam) or CD36 (NB400‐144, Novus) diluted to 1:50 and 1:200 respectively, using the DAKO EnVisionTM+ System (DAKO, Glostrup, Denmark) as described by the manufacturer.

Techniques: Staining, Activity Assay, Control

Journal: Liver International

Article Title: Hypoxia‐inducible factor 2α drives hepatosteatosis through the fatty acid translocase CD36

doi: 10.1111/liv.14519

Figure Lengend Snippet: HIF2α deficiency attenuates Vhl inactivation‐induced hepatic CD36 overexpression. A, Representative blots with the indicated antibodies and densitometric analysis from all blots. B, Representative 10X and 40X images of HIF2α immunostaining, and quantification of nuclear HIF2α‐expressing cells. Scale bar 100 and 50 µm respectively. C, Representative 20× and 40× images of CD36 immunostaining, and quantification of CD36‐expressing cells. Scale bar 100 and 50 µm respectively. Experimental groups: Control, Vhl f/f ‐deficient mice and Vhl f/f Hif2α f/f ‐deficient mice (n = 6‐8 animals/group). ** P < .01 and *** P < .005, Vhl f/f or Vhl f/f Hif2α f/f ‐deficient vs Control mice; ### P < .005, Vhl f/f Hif2α f/f vs Vhl f/f ‐deficient mice

Article Snippet: Paraffin‐embedded liver biopsy sections (4 μm thick) were immunostained with a primary rabbit antibody against HIF2α (ab199, Abcam) or CD36 (NB400‐144, Novus) diluted to 1:50 and 1:200 respectively, using the DAKO EnVisionTM+ System (DAKO, Glostrup, Denmark) as described by the manufacturer.

Techniques: Over Expression, Immunostaining, Expressing, Control

Journal: Liver International

Article Title: Hypoxia‐inducible factor 2α drives hepatosteatosis through the fatty acid translocase CD36

doi: 10.1111/liv.14519

Figure Lengend Snippet: Expression of HIF2α and CD36 is increased within the liver of NAFLD patients. A, Representative 10X images of haematoxylin/eosin (H&E) staining. Scale bar 100 µm. B, NAFLD activity score. C, Representative 20× and 40× images of HIF2α immunostaining, and quantification of nuclear HIF2α‐expressing cells. Scale bar 100 and 50 µm respectively. D, Representative 20× and 60× images of CD36 immunostaining, and quantification of CD36‐expressing cells. Scale bar 100 and 50 µm respectively. E, CD36 and EPO mRNA levels. F, Correlation in the study population of matched mRNA expression levels. Study population: Normal liver (NL) individuals (n = 18), NAFL patients (n = 18) and NASH patients (n = 15). ** P < .01 and *** P < .005, NAFL or NASH vs NL

Article Snippet: Paraffin‐embedded liver biopsy sections (4 μm thick) were immunostained with a primary rabbit antibody against HIF2α (ab199, Abcam) or CD36 (NB400‐144, Novus) diluted to 1:50 and 1:200 respectively, using the DAKO EnVisionTM+ System (DAKO, Glostrup, Denmark) as described by the manufacturer.

Techniques: Expressing, Staining, Activity Assay, Immunostaining

Journal: Open journal of ophthalmology

Article Title: Novel Mechanistic Interplay between Products of Oxidative Stress and Components of the Complement System in AMD Pathogenesis

doi: 10.4236/ojoph.2016.61006

Figure Lengend Snippet: (A) CD36 protein level increased following treatment with OxLDL. ARPE-19 cells were treated with 50 μg/mL of native LDL, OxLDL or OxLDL and pre-incubated with the equal amount (50 μg/mL) of recombined rCFHR1 or rCFH as indicated, for 18 hours. The protein levels were assessed via SDS-PAGE and western blot using anti CD36 antibody. (B) CFH, but not CFHR1, inhibited expression of IL-6 stimulated by OxLDL. Gene expression was assayed by quantitative PCR on mRNA from ARPE19 cells treated with 50 μg/mL of native LDL, OxLDL or OxLDL pre-incubated with the equal amount (50 μg/mL) of recombined rCFHR1 or rCFH for 18 hours. Relative mRNA levels of indicated genes were calculated by normalizing results with GAPDH and are expressed relative to untreated samples. Results are shown as mean ± SEM. N = 6, * P < 0.05.

Article Snippet: This was followed by overnight incubation at 4 C in the blocking buffer containing rabbit primary antibodies against CD36 (Abcam, ab133625, 1:500).

Techniques: Incubation, SDS Page, Western Blot, Expressing, Real-time Polymerase Chain Reaction